

Dr. Trevor Hawkins, a distinguished entrepreneur, scientist, and leader with experience in global healthcare companies, has joined the Supervisory Board of Genomtec S.A.

Genomtec S.A., a leading molecular diagnostics company headquartered in Wroclaw (GPW ticker: GMT), announces that the Extraordinary General Meeting of Shareholders of the company appointed Dr. Trevor Hawkins to the Supervisory Board as of April 22, 2024.

Miron Tokarski, co-founder, shareholder, and CEO of Genomtec, comments: "We are very pleased that Dr. Trevor Hawkins – a seasoned leader in business development, R&D, and commercial operations at global healthcare companies, has agreed to join the Supervisory Board of Genomtec. Together with Mr. Gualtiero Garlasco - a veteran of the MedTech industry with vast experience in business development, who was recently appointed to the Supervisory Board, our company has gained two world-class experts who will provide significant support in achieving the company's strategic goals and developing our innovative technology in the field of genetic diagnostics in infectious diseases and oncology."

Dr. Trevor Hawkins brings to the Supervisory Board of Genomtec a wealth of experience, including serving as Director of the Human Genome Project at the U.S. Department of Energy and most recently in leadership roles at GE, Philips, Siemens, and HP. Dr. Hawkins currently sits on a number of Boards in the health and life science industry. Commenting on the appointment, Dr. Hawkins said "I am very excited to join the Supervisory Board of Genomtec, as distributed, point of care diagnostics becomes a key aspect of post-covid healthcare. The unique technological approach taken by Genomtec answers key questions from physicians, patients, and payors."

About Genomtec

Genomtec is a MedTech company specializing in the development of advanced technologies in the field of genetic diagnostics. The company's flagship project is the Genomtec ID mobile diagnostic system. The system allows for fast and precise molecular analysis outside the laboratory environment without the need to involve qualified laboratory personnel. The solution uses microfluidic technology and proprietary patented SNAAT isothermal technology. The Genomtec technology is protected by 11 patents in Europe, the USA and Japan, and over 35 patent pending applications on global markets.

The company has EU CE-IVD certification for the Genomtec ID RP5-PLEX diagnostic panel, which simultaneously detects the presence of the most common respiratory tract infections.

The company's registered office is located in Wrocław, Poland. Genomtec also has a branch in the UK, where part of the international research and engineering team is located.



More information is available on the page: www.genomtec.com

Media Contact:

Michał Wierzchowski

Tel.: +48 531 613 067

michal.wierzchowski@ccgroup.pl

Contact for investors:

Agata Dzieciotowska

Tel.: +48 606 205 119

agata.dzieciolowska@ccgroup.pl

Małgorzata Młynarska

Tel.: +48 697 613 709

malgorzata.mlynarska@ccgroup.pl